Document:

Service Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 1

 

 

Exhibit 4.17

 

THE SYMBOL “[****]” DENOTES PLACES WHERE
PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Amendment 1 to The service
Agreement A is made and entered in August 17th, 2011 (the “Amendment”).

 

	1.		DESCRIPTION OF THE EXTRA WORK

			

Approximately 1 g of [****] lot number [****] was received from [****]
[****] for supplier qualification.  

A supplier qualification analysis will have to be performed and will
consist of verification of the results included in the certificate of analysis of the supplier. The following tests will be
performed on this lot:

 

		1.	IR (90$),

		2.	Assay (130$),

		3.	Impurities (190$)

		4.	Water content (85$).

 

	2.		COST AND PAYMENTS

	2.1		The cost of the Services for the Extra Work detailed
in section 1 is $495 USD.

	2.2		The Client shall pay to Corealis in United-States
currency ($USD) upon the reception of the invoice.

IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. 

	Corealis Pharma Inc.______	 	7810962 Canada Inc.
	 	 	 
	Per: /s/___________________	 	Per: /s/ Alain Guimond PhD
	 	 	 	 
	Name: Yves Roy, Ph.D.	 	Name: Alain Guimond PhD
	 	 	 
	Title: President	 	Title: Senior director of ResearchExhibit 4.18

 

THE SYMBOL
“[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.
SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Service Agreement
– A

Formulation
development of RHB-105 in oral solid dosage form and manufacture of clinical supplies

Amendment
2

 

Amendment 2 to The service Agreement A is
made and entered in September 30th, 2011 (the “Amendment”)

 

1. DESCRIPTION OF THE EXTRA WORK

Reception, the shipping and the
storage of one additional Lot of Rifabutin and Omneprazole in Corealis ' GMP warehouse as per section (2.5 a) service agreement
A

 

Charges as per the following table:

 

	Description	Amount
	 	 
	Extra Work as per section (2.5 a) service agreement A:	 
	 	 	 
	•	Omeprazole customs charges (Ref.: invoice no.  407084173 1-01) ($442.74 CDN x 0.96 (exchange rate))	$425.03
	•	Omeprazole customs charges & local transportation (Ref.: invoice no.  407084173 1-02) ($ 145.00 CDN x 0.96 (exchange rate))	$139.20
	•	Rifabutin customs charges (Ref.: invoice no.407083673 1-01) ($ 105.00 CDN x 0.96 (exchange rate))	$100.80
	•	GMP material storage & handling for 1 additional Lot of Omeprazole	$200.00
	•	Technical support 0.5 hours ($ 250.00 I hours)	$125.00
	 	 	 
	 	 	 
	 	Total charges  ($USD)                                	$990.03

 

 

2. COST AND PAYMENTS

 

2.1 The cost of the Services for the
Extra Work detailed in section 1 is $ 990.03

2.2 The Client shall pay to Corealis
the following installments in United-States currency

($USD) upon reception of the invoice.

 

IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. 

 

	Corealis Pharma Inc.	 	7810962 Canada Inc.	 
	Per:	 /s/	 	Per: 	/s/ Alain Guimond PhD	 
	Name: Yves Roy, Ph.D.	 	Name: Alain Guimond PhD	 
	Title: President	 	Title: Senior director of ResearchService Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 3

 

Exhibit 4.19

 

THE SYMBOL “[****]” DENOTES PLACES WHERE
PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Amendment 3 to The service
Agreement A is made and entered in April 19th, 2012 (the “Amendment”).

 

	1.		DESCRIPTION OF THE EXTRA WORK

			

The
Client requested that the GMP Omeprazole magnesium API and GMP Amoxicillin API and GMP Rifabutin API would be analyzed by Corealis
at their reception at the Corealis] facility for full testing and not only ID testing.

 

	a.		GMP Omeprazole magnesium API analytical release testing

 

	ITEM	Cost (USD$)	 
	 	 	 
	ID testing	 	 
	IR-Method qualification, set-up and analysis*	0$	 
	[****]	200$	 
	 	 	 
	Assay	 	 
	Method qualification	2,000$	 
	Set-up	605$	 
	Analysis	575$	 
	 	 	 
	Related substances	 	 
	Method qualification	2,500$	 
	Set-up**	0$	 
	Analysis	795$	 
	 	 	 
	Residual solvents	 	 
	Method A: [****]	 	 
	[****]	14,000$	 
	Analysis	1,200$	 
	 	 	 
	Water - Karl Fisher Titration (USP <921>)	 	 
	Analysis	165$	 
	 	 	 
	Appearance	 	 
	Analysis	85$	 
	 	 	 
	[****]	 	 
	 	 	Analysis	75$	 

 

 

	Corealis	Page 1 of 5	 
	Date: April 19th, 2012	 	 

     

     

    

Service Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 3

 

 

	[****]	Analysis	170$	 
	 	 	 
	[****]	 	 
	Analysis	550$	 
			 
	Report****	688$	 
		_______
			 
	Sub total for section 1. a.	23,608$	 
	 	 	 
	b. GMP Amoxicillin trihydrate API analytical release testing
			 
	ITEM	Cost (USD$)	 
			 
	ID testing	 	 
	IR-Method qualification,
set-up and analysis*	0$	 
		 	 
	Assay		 
	Method qualification	2,000$	 
	Set-up	605$	 
	Analysis	575$	 
			 
	Related substances	 	 
	Method qualification	2,500$	 
	Set-up**	0$	 
	Analysis	795$	 
		 	 
	pH	 	 
	Analysis	85$	 
	 	 	 
	Residual solvents	 	 
	[****]	 	 
	[****]	 	 
	[****]	 	 
	[****]	30,000$	 
	[****]	1,800$	 
	 	 	 
	Water - Karl Fisher Titration (USP <921>)	 	 
	Analysis	165$	 
	 	 	 
	Appearance	 	 
	Analysis	85$	 
	 	 	 
	Crystallinity	 	 
	Analysis	550$	 
	 	 	 
	Report****	1,175$	 
	 	_______	 
	 	 	 
	Sub total for section 1. b.	40,335$	 
	 	 			 

 

	Corealis	Page 2 of 5	 
	Date: April 19th, 2012	 	 

     

     

    

Service Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 3

 

 c. GMP Rifabutin API analytical release testing 

 

	ITEM	Cost (USD$)		 
	 	 	 
	ID testing	 	 
	IR-Method qualification,
set-up and analysis*	0$	 
	[****]	575$	 
		 	 
	Assay		 
	Method qualification	2,000$	 
	Set-up	605$	 
	Analysis	575$	 
		 	 
	Related substances		 
	Method qualification	2,500$	 
	Set-up**	0$ 
	Analysis	795$	 
		 	 
	Water - Karl Fisher Titration (USP <921>)	165$	 
	Analysis		 
			 
	Limit of N-Iso Butylpiperidone (TLC)	 	 
	Qualification,
set-up and analysis	1,650$	 
			 
	Residual solvents	 	 
	[****].	 	 
	[****].		 
	[****]	24,000$	 
	Analysis	1,800$	 
	Qualification
[****]***	2,000$	 
	 	 	 
	Appearance	 	 
	Analysis	85$	 
	 	 	 
	Report****	1,103$	 
	 	_______	 
	 	 	 
	Sub total for section 1. c.	37,853$	 
	 	_______	 
	 	 	 
	Total cost of the amendment	101,795$	 
	* Already included in Service Agreement A.	 	 
	 	 			 

 

	Corealis	Page 3 of 5	 
	Date: April 19th, 2012	 	 

 

     

     

    

Service Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 3

 

** Included in the set-up cost of the Assay.

***Analysis to be outsourced to a Corealis qualified vendor.
[****] in Toronto using the validated analytical methods of [****].

**** Cost for the documentation and the CofA- 3% of the total cost of the analysis.

 

		2.	COST AND PAYMENTS

		2.1	The cost of the Services for the Extra Work detailed in section
1 is:

		2.1.1	$101,795 if the following installments are:

		·	50% at the signature of this Agreement; and

		·	the balance at the completion of the release testing.

OR

		2.1.2	$89,783 if $89,783 is paid within 7 days from the signature of this
Agreement.

 

		2.2	The Client shall pay to Corealis the following installments in
United-States currency ($USD):

 

		3.	TIMELINES FOR AMENDMENT 3

[****]

 

 

 

 

 

 

IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. 

 

	Corealis	Page 4 of 5	 
	Date: April 19th, 2012	 	 

     

     

    

Service Agreement – A

Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies

Amendment 3

 

 

	Corealis Pharma Inc.	 	7810962	 
	Canada Inc.	 	 
	 	 	 
	Per: /s/___________________	 	Per: /s/ Alain Guimond PhD
	 	 	 	 
	Name: Yves Roy, Ph.D.	 	Name: Alain Guimond PhD
	 	 	 
	Title: President	 	Title: Senior director of Research

 

 

 

 

 

 

 

 

 

	Corealis	Page 5 of 5	 
	Date: April 19th, 2012Exhibit 4.1

THE BANK OF NEW YORK MELLON

NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON

 

 

2 HANSON PLACE, 12TH FLOOR, BROOKLYN,
N.Y. 11217

 

 

 

September 10, 2015

 

Hennion & Walsh, Inc.

2001 Route 46, Waterview Plaza

Parsippany, New Jersey 07054

 

Smart Trust, New Jersey Municipal Portfolio
of Closed-End Funds Trust, Series 7

 

Dear Sirs:

The Bank of New York
Mellon is acting as trustee for Smart Trust, New Jersey Municipal Portfolio of Closed-End Funds Trust, Series 7 set forth above
(the “Trust”). We enclosed a list of the Securities to be deposited in the Trust on the date hereof. The prices
indicated therein reflect our evaluation of such Securities as of close of business on September 9, 2015, in accordance with the
valuation method set forth in the Standard Terms and Conditions of Trust and Trust Agreement. We consent
to the reference to The Bank of New York Mellon as the party performing the evaluations of the Trust Securities in the Registration
Statement (No. 333-205909) filed with the Securities and Exchange Commission with respect to the registration of the sale of the
Trust Units and to the filing of this consent as an exhibit thereto.

 

 

Very truly yours,

 

/s/ GERARDO CIPRIANO________________

Gerardo Cipriano

Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]